Top

Published in:

01-06-2017 | Original Contributions

Fasting Circulating Glicentin Increases After Bariatric Surgery

Authors: Juliette Raffort, Patricia Panaïa-Ferrari, Fabien Lareyre, Pascale Bayer, Pascal Staccini, Patrick Fénichel, Giulia Chinetti

Published in: Obesity Surgery | Issue 6/2017

Abstract

Introduction

Bariatric surgery including the Roux-en-Y gastric bypass (RYGB) and the laparoscopic sleeve gastrectomy (LSG) is a well-established therapeutic option for patients with morbid or severe obesity. Metabolic modifications observed after bariatric surgery are thought to be, at least partly, linked to hormonal changes. While variation of several proglucagon-derived peptides during bariatric surgery is well documented, little is known about glicentin. The aim of this study was to investigate circulating glicentin variations after bariatric surgery.

Material and Methods

Thirty patients eligible for bariatric surgery (18 RYGB and 12 LSG procedures) were prospectively included in the University Hospital of Nice. Clinical data and fasting biological parameters were recorded preoperatively, at 3, 6, and 12 months after bariatric surgery.

Results

The median age of patients was 51 years (35–56) with 33.3% men. Fasting glicentin concentration increased progressively after bariatric surgery from 6 months and was more marked at 12 months (14 ± 3.6 pmol/L at baseline vs 19.7 ± 2.7 pmol/L at 12 months for RYGB and 12.5 ± 1.4 vs 16.4 ± 1.8 pmol/L for LSG, respectively). Compared to preoperative values, the fold increase of glicentin at 12 months was 2 ± 0.2 in the RYGB group and 1.6 ± 0.3 in the LSG group. Glicentin variation after surgery did not correlate with anthropometric, glycemic, or lipid parameter modifications.

Conclusion

Fasting glicentin level increases after bariatric surgery suggesting the potential interest of this peptide as a player and/or a marker of physiological changes after bariatric surgery.

Available only for authorised users

Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRef

Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.PubMedCrossRef

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.PubMedCrossRef

Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19(12):1605–11.PubMedCrossRef

Piche ME, Auclair A, Harvey J, et al. How to choose and use bariatric surgery in 2015. Can J Cardiol. 2015;31(2):153–66.PubMedCrossRef

Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13(6):983–8.PubMedCrossRef

Papamargaritis D, Miras AD, le Roux CW. Influence of diabetes surgery on gut hormones and incretins. Nutr Hosp. 2013;28(Suppl 2):95–103.PubMed

Ionut V, Burch M, Youdim A, et al. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring). 2013;21(6):1093–103.CrossRef

Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55(7):1890–901.PubMedCrossRef

10.

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.PubMedCrossRef

11.

Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997;59:257–71.PubMedCrossRef

12.

Hage MP, Safadi B, Salti I, et al. Role of gut-related peptides and other hormones in the amelioration of type 2 diabetes after Roux-en-Y gastric bypass surgery. ISRN Endocrinol. 2012;2012:504756.PubMedPubMedCentralCrossRef

13.

Sala PC, Torrinhas RS, Giannella-Neto D, et al. Relationship between gut hormones and glucose homeostasis after bariatric surgery. Diabetol Metab Syndr. 2014;6(1):87.PubMedPubMedCentralCrossRef

14.

Kirkegaard P, Moody AJ, Holst JJ, et al. Glicentin inhibits gastric acid secretion in the rat. Nature. 1982;297(5862):156–7.PubMedCrossRef

15.

Myojo S, Tsujikawa T, Sasaki M, et al. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro. J Gastroenterol. 1997;32(3):300–5.PubMedCrossRef

16.

Pellissier S, Sasaki K, Le-Nguyen D, et al. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine. Neurogastroenterol Motil. 2004;16(4):455–63.PubMedCrossRef

17.

Tomita R, Igarashi S, Tanjoh K, et al. Role of recombinant human glicentin in the normal human jejunum: an in vitro study. Hepato-Gastroenterology. 2005;52(65):1459–62.PubMed

18.

Ohneda A, Ohneda K, Nagasaki T, et al. Insulinotropic action of human glicentin in dogs. Metabolism. 1995;44(1):47–51.PubMedCrossRef

19.

Manell H, Staaf J, Manukyan L, et al. Altered plasma levels of glucagon, GLP-1 and glicentin during OGTT in adolescents with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2016;101(3):1181–9.PubMedCrossRef

20.

Naito H, Ohneda A, Kojima R, et al. Plasma glicentin in diabetic and gastrectomized patients. Regul Pept. 1999;79(1):55–61.PubMedCrossRef

21.

Wewer Albrechtsen NJ, Kuhre RE, Torang S, et al. The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. BMC Res Notes. 2016;9:60.PubMedPubMedCentralCrossRef

22.

Gunawardene AR, Corfe BM, Staton CA. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol. 2011;92(4):219–31.PubMedPubMedCentralCrossRef

23.

Rodier G, Magous R, Mochizuki T, et al. Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes. Endocrinology. 1999;140(1):22–8.PubMedCrossRef

24.

Ayachi SE, Borie F, Magous R, et al. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39). Neurogastroenterol Motil. 2005;17(2):302–9.PubMedCrossRef

25.

Quercia I, Dutia R, Kotler DP, et al. Gastrointestinal changes after bariatric surgery. Diabetes Metab. 2014;40(2):87–94.PubMedCrossRef

26.

Ohneda A, Takahashi H, Maruyama Y. Response of plasma glicentin to fat ingestion in piglets. Diabetes Res Clin Pract. 1987;3(2):103–9.PubMedCrossRef

27.

Ohneda A, Kobayashi T, Nihei J, et al. Effect of intraluminal administration of amino acids upon plasma glicentin. Diabetes Res Clin Pract. 1988;5(4):265–70.PubMedCrossRef

28.

Shimizu T, Tadokoro R, Kaneko N, et al. Effects of extremely early enteral feeding on plasma glicentin levels in very-low-birthweight infants. J Paediatr Child Health. 2006;42(10):636–9.PubMedCrossRef

29.

Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89(6):2608–15.PubMedCrossRef

30.

Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741–9.PubMedPubMedCentralCrossRef

31.

Rhee NA, Wahlgren CD, Pedersen J, et al. Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia. 2015;58(10):2254–8.PubMedCrossRef

32.

Zhang F, Strain GW, Lei W, et al. Changes in lipid profiles in morbidly obese patients after laparoscopic sleeve gastrectomy (LSG). Obes Surg. 2011;21(3):305–9.PubMedCrossRef

33.

Oliveira Cda S, Beserra BT, Cunha RS, et al. Impact of Roux-en-Y gastric bypass on lipid and inflammatory profiles. Rev Col Bras Cir. 2015;42(5):305–10.PubMedCrossRef

34.

Ohneda A, Ohneda M. Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas. Tohoku J Exp Med. 1988;155(2):197–204.PubMedCrossRef

35.

Ohneda A, Kobayashi T, Nihei J. Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs. Diabetologia. 1986;29(6):397–401.PubMedCrossRef

36.

Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52.PubMedCrossRef

37.

Bataille D. Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology. J Mol Med (Berl). 2007;85(7):673–84.CrossRef

38.

Bataille D, Dalle S. The forgotten members of the glucagon family. Diabetes Res Clin Pract. 2014;106(1):1–10.PubMedCrossRef

Title: Fasting Circulating Glicentin Increases After Bariatric Surgery
Authors: Juliette Raffort
Patricia Panaïa-Ferrari
Fabien Lareyre
Pascale Bayer
Pascal Staccini
Patrick Fénichel
Giulia Chinetti
Publication date: 01-06-2017
Publisher: Springer US
Published in: Obesity Surgery / Issue 6/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-016-2493-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fasting Circulating Glicentin Increases After Bariatric Surgery

Abstract

Introduction

Material and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Material and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2017

Plasma Apelin and Asymmetric Dimethylarginine (ADMA) Levels Shortly After Laparoscopic Greater Curvature Plication

Taste, Enjoyment, and Desire of Flavors Change After Sleeve Gastrectomy-Short Term Results

Effects of Neighborhood Walkability on Physical Activity and Sedentary Behavior Long-Term Post-Bariatric Surgery

Analysis of Gene Candidate SNP and Ancestral Origin Associated to Obesity and Postoperative Weight Loss in a Cohort of Obese Patients Undergoing RYGB

Roux-En-Y Fistulojejunostomy: a New Therapeutic Option for Complicated Post-Sleeve Gastric Fistulas, Video-Report

Failure of the Obesity Surgery Mortality Risk Score (OS-MRS) to Predict Postoperative Complications After Bariatric Surgery. A Single-Center Series and Systematic Review